Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$127,173 | -$121,832 | -$115,438 | -$111,694 |
| Dep. & Amort. | $1,772 | $1,169 | $1,324 | $915 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $21,345 | $25,616 | $25,144 | $20,931 |
| Change in WC | $4,216 | -$10,479 | $932 | $3,625 |
| Other Non-Cash | -$3,048 | -$1,537 | $4,309 | $2,692 |
| Operating Cash Flow | -$102,888 | -$107,063 | -$83,729 | -$83,531 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$764 | -$3,513 | -$3,019 | -$2,323 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$52,694 | -$221,633 | -$119,223 | -$261,480 |
| Inv. Sales/Matur. | $143,649 | $190,500 | $203,933 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $90,191 | -$34,646 | $81,691 | -$263,803 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$395 | $0 | $0 | $0 |
| Stock Issued | $329 | $135,731 | $0 | $161,424 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$54 | $664 | $815 | $3,473 |
| Financing Cash Flow | -$120 | $136,395 | $815 | $164,897 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$12,817 | -$5,314 | -$1,223 | -$182,437 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $29,335 | $34,649 | $35,872 | $218,309 |
| End Cash | $16,518 | $29,335 | $34,649 | $35,872 |
| Free Cash Flow | -$103,652 | -$110,576 | -$86,748 | -$85,854 |